Clinipace

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that treat cancer, cardiovascular and autoimmune diseases and viral infections. BioCryst uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry and computer modeling. In structure-based drug design, scientists use detailed knowledge of the active sites of protein targets associated with particular diseases to design synthetic compounds that fight the disease. Structure-based drug design aims to create a molecule that will bind to the active site of a targeted enzyme, thereby preventing the normal chemical reaction and ultimately halting the progression of the disease. BioCryst was founded in 1986. The Company's stock is traded on the NASDAQ exchange under the symbol BCRX.

Founded in 1988, EI is a full-service consulting firm that employs a staff of more than 125 personnel. It offers consulting services in the areas of environment, safety, industrial hygiene, occupational health and engineering. Headquartered in Morrisville, N.C., the company provides clients with practical solutions for the management of asbestos and lead-based paint hazards. EI also offers expertise in various safety program areas, including fire protection, personal protective equipment, crane usage, power generation, and electrical and laboratory safety. In addition, it provides industrial ventilation assessment and design, as well as radon testing and mitigation services. EI additionally offers courses in occupational health, safety and compliance, and asbestos and mold management. The company maintains facilities in South Carolina, Virginia, Kentucky, Florida and Texas.